NextCell Pharma AB
65G
Company Profile
Business description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWET: +46 87355595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
stocks
Is it time to bail on Australian stocks?
Is your home bias costing your portfolio better returns?
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.50 | 25.20 | 0.28% |
| CAC 40 | 8,140.06 | 49.78 | 0.62% |
| DAX 40 | 25,497.85 | 95.57 | 0.38% |
| Dow JONES (US) | 52,093.11 | 328.09 | -0.63% |
| FTSE 100 | 10,727.08 | 68.95 | 0.65% |
| HKSE | 24,713.78 | 46.54 | 0.19% |
| NASDAQ | 25,981.57 | 204.84 | -0.78% |
| Nikkei 225 | 63,923.00 | 438.90 | 0.69% |
| NZX 50 Index | 13,622.72 | 138.50 | 1.03% |
| S&P 500 | 7,585.73 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,696.50 | 24.00 | 0.28% |
| SSE Composite Index | 3,891.60 | 27.32 | 0.71% |